Can I Take Resveratrol With CJC-1295?

What Is CJC-1295 and Why Are Women Using It?

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH). The modified GRF version most commonly prescribed through compounding pharmacies carries a drug affinity complex (DAC) that extends its half-life from minutes to approximately 6 to 8 days. Without DAC, the peptide is often called modified GRF 1-29, and its half-life is closer to 30 minutes.

Women are seeking CJC-1295 most often in perimenopause and after menopause, when the natural pulsatile secretion of growth hormone drops significantly. GH pulse amplitude declines by roughly 14% per decade from the third decade onward, and that decline accelerates around the menopause transition. The resulting drop in IGF-1 tracks with increased visceral fat, reduced lean mass, fatigue, and slower tissue repair, all complaints that bring women into telehealth consults.

How CJC-1295 Works in the Female Body

CJC-1295 binds the GHRH receptor on pituitary somatotrophs, triggering pulsatile GH release. In women, GH secretion is already sexually dimorphic. Estrogen amplifies GH pulse amplitude, which is why pre-menopausal women have higher basal GH than age-matched men but lower IGF-1 (because estrogen also blunts hepatic IGF-1 production). This creates a situation where the same CJC-1295 dose may produce a different IGF-1 response depending on your estrogen status. A post-menopausal woman not on hormone therapy may see a more pronounced IGF-1 rise than a woman still cycling, not because the peptide is more potent, but because her baseline hepatic sensitivity is different.

The 503A Compounding Context

CJC-1295 is not FDA-approved. It is available only through compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act, typically prescribed off-label by physicians practicing in longevity or functional medicine. The FDA has periodically raised concerns about compounded peptides and their inclusion on the "difficult to compound" list, so product availability can shift. This regulatory uncertainty is a real clinical consideration, not a footnote.

What Is Resveratrol and What Does It Actually Do?

Resveratrol is a polyphenol found in grape skins, red wine, peanuts, and Japanese knotweed. It is widely marketed for cardiovascular and longevity benefits. The proposed mechanisms include SIRT1 activation, AMPK stimulation, and antioxidant activity. In practice, its oral bioavailability is low: roughly 70% of an oral dose is absorbed but undergoes extensive first-pass metabolism, leaving systemic bioavailability well below 1% for the unmetabolized parent compound.

That low bioavailability complicates both efficacy and interaction claims. What reaches systemic circulation is mostly sulfate and glucuronide conjugates. Whether those conjugates retain meaningful biological activity is still debated.

Resveratrol as a Phytoestrogen

This is the detail most coverage misses. Resveratrol binds estrogen receptor beta (ERbeta) with moderate affinity, and to a lesser extent estrogen receptor alpha (ERalpha). In vitro studies show resveratrol acts as an ERbeta agonist and a partial ERalpha agonist or antagonist depending on the tissue context. That tissue selectivity means its estrogenic effect in breast tissue may differ from its effect in bone or the cardiovascular system, which matters a great deal when you are counseling a woman with a history of hormone-sensitive cancer.

Resveratrol and CYP Enzymes

Resveratrol inhibits CYP3A4, CYP2C9, and CYP2E1 in vitro. At doses achievable with standard supplements (150 mg to 500 mg per day), in vivo CYP3A4 inhibition appears modest in most human pharmacokinetic studies, but it is not zero. Women on medications that depend heavily on CYP3A4 clearance, including some oral contraceptives, certain statins, and immunosuppressants, should be aware of this.

CJC-1295 is a peptide. It is not metabolized by CYP enzymes. It is cleared by proteolytic cleavage and renal filtration, so resveratrol's CYP3A4 inhibition does not directly slow CJC-1295 clearance. This is the most commonly asked question, and the answer is: no direct pharmacokinetic interaction through CYP pathways.

Is There a Direct Interaction Between Resveratrol and CJC-1295?

The short answer: no confirmed direct interaction has been documented in human studies, because the combination has never been formally studied in humans.

To reason through the evidence gap systematically, it helps to separate interaction types.

Pharmacokinetic Interactions (How Each Drug Is Processed)

| Mechanism | Resveratrol | CJC-1295 | Interaction Risk | |---|---|---|---| | CYP3A4 metabolism | Inhibitor | Not a CYP substrate | Low | | Plasma protein binding | High (albumin) | Minimal free peptide; DAC version binds albumin | Theoretical displacement, not documented | | Renal clearance | Minor route | Primary route for metabolites | No overlap | | GI absorption | Extensive first-pass | Subcutaneous injection; bypasses GI | No overlap |

Albumin binding is worth a moment. The DAC version of CJC-1295 is specifically engineered to bind albumin in plasma, which is what extends its half-life. Resveratrol also binds albumin. Whether high-dose resveratrol could theoretically displace CJC-1295 from albumin and alter its pharmacokinetics is not something any published study has tested. The displacement risk is considered low at normal supplement doses, but it is a data gap, not a cleared concern.

Pharmacodynamic Interactions (How Each Agent Affects the Body)

This is where the more interesting and less-answered questions live.

Resveratrol has been shown to stimulate GH secretion in some animal models. A 2012 study in aged rats found resveratrol increased pulsatile GH secretion and partially restored the age-related decline. If resveratrol independently nudges GH upward, combining it with CJC-1295 could in theory produce an additive effect on GH and IGF-1. For most healthy women this is unlikely to cause harm at standard doses, but women with a personal or strong family history of certain IGF-1-sensitive cancers (particularly premenopausal breast cancer and colorectal cancer) should discuss the implications with their oncologist before stacking any GH secretagogue with a compound that may further raise GH signaling.

Resveratrol's ERbeta activity adds a second pharmacodynamic layer. Estrogen itself modulates the GH axis. ERbeta agonism in the hypothalamus can affect GHRH release and somatostatin tone. Research has shown estrogen receptor signaling in the arcuate nucleus influences GH pulse frequency. Whether the degree of ERbeta activation produced by realistic resveratrol doses is sufficient to meaningfully alter GH pulsatility in women is unknown. But in a post-menopausal woman already on CJC-1295 to restore GH pulsatility, adding a compound with hypothalamic estrogenic effects creates a biologically plausible but unquantified variable.

How This Combination Looks Across Life Stages

Reproductive Years (Ages 18 to 40)

Women in their reproductive years have the highest endogenous estrogen levels and the least to gain from either agent in most cases. GH secretion is generally adequate. Resveratrol's estrogenic activity sits on top of an already-active estrogen milieu, making interactions with the menstrual cycle possible. One small RCT found 1,500 mg per day of resveratrol reduced circulating estradiol and shortened luteal phase in healthy premenopausal women, which is clinically relevant if you are trying to conceive or managing cycle-dependent symptoms. Adding CJC-1295 to this mix in a reproductive-age woman without a clear GH-deficiency diagnosis is hard to justify given the absence of safety data.

Trying to Conceive

Stop both. See the pregnancy and lactation section below.

Perimenopause (Ages 40 to 55, approximately)

This is the life stage where the combination is most commonly requested. Estrogen is fluctuating and declining. GH secretion is also declining. Resveratrol's partial ERbeta agonism is sometimes pitched as a "natural" estrogen support during this window. CJC-1295 is pitched to restore the GH pulse. The appeal is understandable.

Resveratrol at 75 mg twice daily improved insulin sensitivity and well-being scores in a placebo-controlled trial of 80 postmenopausal women over 14 weeks. That is encouraging metabolic data. No equivalent trial in perimenopausal women taking CJC-1295 simultaneously exists. If you are in perimenopause and want to try both, the reasonable approach is to start one at a time with IGF-1 monitoring, not to add both simultaneously.

Post-Menopause

The strongest resveratrol data in women comes from post-menopausal cohorts. Post-menopausal women also show the most pronounced IGF-1 response to GHRH analogues, partly because of reduced hepatic IGF-1 suppression without estrogen. This amplified IGF-1 response means that monitoring is more important here, not less.

Women on concurrent hormone therapy (MHT) in post-menopause face a three-way consideration: exogenous estrogen, resveratrol's ERbeta activity, and CJC-1295's IGF-1 stimulation. Oral estrogen already reduces IGF-1 by increasing hepatic IGF-1 binding protein production; transdermal estrogen does so less. Adding CJC-1295 to push IGF-1 back up while taking oral MHT creates an opposing hormonal tug-of-war that no published trial has mapped out in women.

Pregnancy, Lactation, and Contraception

Both CJC-1295 and resveratrol are contraindicated during pregnancy and breastfeeding. If you are pregnant, trying to conceive, or breastfeeding, do not take either agent.

CJC-1295 carries no formal FDA pregnancy category because it has never been approved. No human pregnancy safety data exists. Animal studies are limited and cannot be extrapolated confidently to human pregnancy. Growth hormone axis manipulation during fetal development carries theoretical risks to fetal growth regulation. The precautionary recommendation is unambiguous: stop CJC-1295 before attempting conception. Because the DAC version has a half-life of 6 to 8 days, full clearance takes approximately 4 to 6 weeks after the last injection.

Resveratrol at high doses has demonstrated embryotoxicity and developmental disruption in animal models, including effects on placental development. Human data is absent. Resveratrol transfers into breast milk in animal studies; human lactation transfer data does not exist, so the precautionary recommendation is to avoid it throughout breastfeeding.

Contraception note: if you are using CJC-1295 and on hormonal contraception that relies on CYP3A4 for metabolism (including certain combined oral contraceptives), high-dose resveratrol's CYP3A4 inhibition is a theoretical concern for contraceptive efficacy, though the clinical magnitude at standard supplement doses is unlikely to be significant. Discuss this with your prescriber if you are in this situation.

Women who are using CJC-1295 and are sexually active with pregnancy possible should use a reliable non-hormonal contraceptive method or a hormonal method and document that discussion with their prescriber. This is not a drug with a cleared pregnancy profile.

Who This Combination May Be Appropriate For (and Who It Is Not)

Potentially Appropriate

• Post-menopausal women with documented low IGF-1 and metabolic indications, under prescriber supervision, who understand the evidence is limited
• Women in perimenopause with concurrent metabolic concerns (insulin resistance, dyslipidemia) who are working with a clinician tracking IGF-1, fasting glucose, and lipids quarterly
• Women who have already tried lifestyle optimization, are not on hormone-sensitive medications metabolized by CYP3A4, and have no personal history of hormone-sensitive malignancy

Not Appropriate

• Women who are pregnant, breastfeeding, or actively trying to conceive
• Women with a personal history of hormone-receptor-positive breast cancer, endometrial cancer, or ovarian cancer (resveratrol's ERbeta activity and IGF-1 stimulation are both concerns here)
• Women with active acromegaly or pituitary tumors
• Women with type 1 or poorly controlled type 2 diabetes without close glucose monitoring (CJC-1295 can impair insulin sensitivity acutely by raising GH, and resveratrol has variable glycemic effects depending on dose and baseline status)
• Women taking CYP3A4-sensitive medications at narrow therapeutic windows (tacrolimus, cyclosporine, certain antiretrovirals)

What the Evidence Gap Means for You

Women have been under-represented in peptide research broadly. Most CJC-1295 pharmacokinetic data comes from a small number of trials conducted predominantly in men or in mixed-sex cohorts without sex-stratified reporting. Resveratrol trials have somewhat better female representation, particularly in post-menopausal populations, but combination studies with GH secretagogues simply do not exist.

This matters because it means every clinical recommendation for this pairing is extrapolated from mechanistic reasoning, not from a trial that enrolled women and measured what happened. That is not a reason to panic, but it is a reason to set expectations clearly with your prescribing clinician and to insist on monitoring rather than assumption.

The Endocrine Society's clinical practice guideline on growth hormone deficiency in adults recommends IGF-1 measurement as the primary monitoring parameter, and that guidance applies even when the GH stimulus is a secretagogue rather than exogenous GH. If your prescriber is not checking IGF-1 at baseline and at 3 months after starting CJC-1295, that is a gap in care.

Practical Monitoring If You Are Already Taking Both

If you are currently taking resveratrol and CJC-1295 together and want to continue while assessing your individual response, a reasonable monitoring framework includes:

• IGF-1 (serum): baseline before starting CJC-1295, then at 6 to 8 weeks, then every 3 months. Target range is the mid-normal range for your age, not the upper quartile.
• Fasting glucose and fasting insulin: at baseline and every 3 months. CJC-1295 raises GH acutely, and GH is a counter-regulatory hormone that can blunt insulin action.
• Estrogen-sensitive symptom tracking: note any changes in breast tenderness, vaginal bleeding (if post-menopausal, this is a red flag requiring evaluation), or fibroid-related symptoms if you have fibroids, given resveratrol's ERbeta activity.
• Lipid panel: resveratrol may modestly improve LDL-C; GH secretagogues can affect lipid partitioning. A 2014 randomized trial found resveratrol 1,000 mg per day reduced LDL-C by 4.5% versus placebo over 3 months in post-menopausal women with type 2 diabetes.
• Blood pressure: both GH and resveratrol can affect vascular tone in opposite directions; tracking is prudent.

If IGF-1 rises above the upper limit of normal for your age, discuss reducing the CJC-1295 dose or frequency before adjusting resveratrol, since the peptide is the more potent GH driver of the two.

Dosing Considerations Specific to Women

The CJC-1295 dose most commonly used in compounding practice is 1 mg to 2 mg subcutaneously once or twice weekly for the DAC version, or 100 mcg to 200 mcg of modified GRF 1-29 nightly for the non-DAC version (often paired with ipamorelin). No dedicated female-specific dosing trial has been published. Given that women may show a more pronounced IGF-1 response per unit of CJC-1295 in the post-menopausal state, starting at the lower end and titrating is rational.

Resveratrol doses in clinical trials have ranged from 75 mg twice daily to 2,000 mg per day, with most tolerability data clustered below 1,000 mg per day. GI side effects (nausea, loose stool) are the most common complaints at higher doses.

"There is no human pharmacokinetic data on resveratrol and CJC-1295 together. We are reasoning from mechanism, not from trial data. Women deserve to know that distinction before they decide whether to combine these agents." Dr. Maya Okafor, MD, WomanRx Editorial Board.